%0 Journal Article
%T First-Line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients
%A Ying Li
%A Lin Run Wang
%A Jian Chen
%A Yan Lou
%A Guo Bing Zhang
%J Disease Markers
%D 2014
%R 10.1155/2014/960458
%X Aim. To evaluate the predictive value of RRM1, ERCCl, and BRCA1 expression in Chinese NSCLC patients treated with gemcitabine and cisplatin. Methods. Real-time fluorescent quantitative PCR was used to determine the RRM1, ERCC1, and BRCA1 mRNA expression levels of peripheral blood in late-stage NSCLC patients. The relationship between peripheral blood and mRNA expression in tumor tissues was analyzed further. Results. In terms of the tumor susceptibility to chemotherapy, the response rate in the low-RRM1-expression group was significantly greater than in the high-expression group (52.9%£¿versus 5.9%, test, ). Subjects with low peripheral blood RRM1 expression survived longer than those with high RRM1 expression (15.5£¿versus 12.0 months, logrank 3.980, ). Linear correlations were observed between peripheral blood and tumor tissue expression levels for RRM1 ) and BRCA1 ). Conclusion. Our study demonstrates increased survival and superior efficacy of gemcitabine and cisplatin combination chemotherapy in the treatment of NSCLC patients with low peripheral blood RRM1 expression. The linear correlations of the relative expression of mRNA were observed between peripheral blood and tumor tissue expression levels for RRM1 and BRCA1. RRM1 gene expression may contribute to chemotherapy sensitivity and may be an indicator of survival. It was significant to individual chemotherapy of patients with advanced NSCLC who do not have sufficient tumor tissue. 1. Introduction In recent years, research has focused on abnormal DNA repair and drug resistance for individualized treatment of lung cancer. Ribonucleotide reductase (RR) catalyzes the formation of deoxyribonucleotides from ribonucleotides. It plays a key role in repairing DNA and it is also an important rate-limiting enzyme during DNA synthesis. The M1 subunit of RR (RRM1) is the nucleotide-binding site, which controls substrate specificity and enzyme activity. RRM1 also is the binding site for chemotherapy drugs such as gemcitabine and other nucleoside analogues [1]. Preclinical studies have shown that patients with low tumor tissue RRM1 expression had greater median length of disease progression and median survival time than did patients with high tumor tissue RRM1 expression. RRM1 expression level is associated with gemcitabine resistance in tumor cells [2, 3]. Therefore, RRM1 expression level is an important benchmark for the selection of patients for gemcitabine chemotherapy. The excision repair cross complementation 1 gene (ERCCl) is involved in DNA damage repair and excision caused by cisplatin drugs. In recent
%U http://www.hindawi.com/journals/dm/2014/960458/